Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) | Request PDF

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) | Request PDF

Comments

Popular posts from this blog

ASCO 2025: Non-Androgen-Receptor–Driven Prostate Cancer: Updates in Biology, Classification, and Management

Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey | Prostate Cancer and Prostatic Diseases

The Other Patient: Care for the Caregivers